Marek Pertkiewicz ^†

• Ausgewählte Literatur von Marek Pertkiewicz

• 1 Koper I, Białas A, Kociszewska D, Noori N, Pertkiewicz M. Aspergillosis – diagnostic and therapeutic difficulties in critically ill surgical patients. Pol Przegl Chir 2013; 85: 608-614
• 2 Jeppesen PB, Pertkiewicz M, Forbes A, Pironi L, Gabe SM, Joly F, Messing B, Loth S, Youssef NN, Heinze H, Berghöfer P. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide – analyses from a randomised, placebo-controlled study. Clin Nutr 2013; 32: 713-721
• 3 OʼKeefe SJ, Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure. Clin Gastroenterol Hepatol 2013; 11: 815-823
• 4 Berghöfer P, Fragkos KC, Baxter JP, Forbes A, Joly F, Heinze H, Loth S, Pertkiewicz M, Messing B, Jeppesen PB. Development and validation of the disease-specific Short Bowel Syndrome-Quality of Life (SBS-QoL) scale. Clin Nutr 2013; 32: 789-796
• 5 Jeppesen PB, Pertkiewicz M, Messing B, Iyer K, Seidner DL, Oʼkeefe SJ, Forbes A, Heinze H, Joelsson B. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology 2012; 143: 1473-1481
• 6 Pironi L, Goulet O, Buchman A, Messing B, Gabe S, Candusso M, Bond G, Gupte G, Pertkiewicz M, Steiger E, Forbes A, Van Gossum A, Pinna AD. Home Artificial Nutrition and Chronic Intestinal Failure Working Group of ESPEN. Outcome on home parenteral nutrition for benign intestinal failure: a review of the literature and benchmarking with the European prospective survey of ESPEN. Clin Nutr 2012; 31: 831-845